TMC Likes Its Options: Hospital Marketer Gains Rights To ProFibrix

The Medicines Company agreed to pay $10 million upfront to ProFibrix for an option to acquire the company outright after Phase III data on the lead biologic, Fibrocaps, read out later this year.